Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

Sangheun Lee, Beom Kyung Kim, Seungup Kim, Soo Young Park, Ja Kyung Kim, Hyun Woong Lee, Junyong Park, doyoung kim, SangHoon Ahn, Won Young Tak, Young Oh Kweon, Jung Il Lee, Kwan Sik Lee, Hyung Joon Kim, KwangHyub Han

Research output: Contribution to journalArticle

19 Citations (Scopus)


Background and Aim: Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). The efficacy and safety of sorafenib as a first-line therapy in Korean patients with advanced HCC were investigated. Methods: From 2007 to 2012, 86 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) treated with sorafenib as a first-line therapy were enrolled from five tertiary hospitals. Predictors of overall survival (OS) and progression-free survival (PFS) were analyzed. Results: The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in Child-Pugh class A. The median OS and PFS were 5.0 (range 4.0-5.9) and 3.2 (range 2.6-3.7) months, respectively. Regarding OS, Child-Pugh class A (6.0 vs 2.8 months), tumor diameter <5cm (6.0 vs 4.3 months), baseline α-fetoprotein <200ng/mL (5.8 vs 4.1 months), and the advent of hand-foot-skin reaction of ≥grade 2 (5.9 vs 4.0 months) were independent favorable predictors (all P<0.05). Similarly, regarding PFS, Child-Pugh class A (4.3 vs 2.1 months), tumor diameter <5cm (3.9 vs 2.8 months), baseline α-fetoprotein <200ng/mL (5.6 vs 2.8 months), and the advent of hand-foot-skin reaction of ≥grade 2 (4.5 vs 2.6 months) were independent favorable predictors (all P<0.05). All toxicities during sorafenib treatment were manageable. Conclusions: Because the efficacy of sorafenib seems marginal in Korean patients with treatment-naïve HCC, how to select candidates with favorable outcomes should be further investigated.

Original languageEnglish
Pages (from-to)1463-1469
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Issue number7
Publication statusPublished - 2014 Jan 1


All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this